For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...

Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...